Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study
Journal of Clinical Oncology · 10.09.2024 · 42 (26) · 3140-3150
DOI: 10.1200/jco.24.00108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2024. Verfasst von Rathana Kim und 33 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Laboratory, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Neoplasm, Residual, Hematopoietic Stem Cell Transplantation, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE BCR::ABL1 quantification is widely regarded as the standard for monitoring measurable residual disease (MRD) in Philadelphia chromosome–positive (Ph+) ALL. However, recent evidence of BCR::ABL1 multilineage involvement questions the significance of BCR::ABL1 MRD. We aimed to define the prognostic role of MRD as assessed by BCR::ABL1 or lymphoid-specific immunoglobulin/T-cell receptor ( IG/TR) gene markers. PATIENTS AND METHODS We conducted BCR::ABL1 and IG/TR quantification after each treatment cycle in 264 patients treated in the GRAAPH-2014 trial, which used four cycles of reduced-intensity chemotherapy with nilotinib, followed by hematopoietic stem-cell transplantation (HSCT). RESULTS Comparing BCR::ABL1 and IG/TR MRD revealed residual BCR::ABL1-positive non-ALL cells in 98 (43%) of 228 patients, defining multilineage Ph+ ALL. Despite poorer BCR::ABL1 responses, patients with multilineage Ph+ ALL had similar disease-free survival (DFS; hazard ratio [HR], 0.83 [95% CI, 0.49 to 1.41]; P = .50). Although BCR::ABL1 response failed to predict outcomes, IG/TR positivity (≥0.01%) was strongly associated with lower DFS (after cycle 2, HR, 2.49 [95% CI, 1.40 to 4.40]; P = .002; after cycle 4, HR, 4.13 [95% CI, 1.82 to 9.38]; P = .001). In multivariable analysis, both IG/TR positivity after cycle 2 and initial WBC count ≥30 × 10 9 /L predicted poorer DFS, enabling to define a high-risk group having a 4-year DFS of 56.5% compared with 87.6% (HR, 3.72 [95% CI, 1.93 to 7.15]; P < .001). Moreover, allogeneic HSCT significantly improved DFS in the high-risk group (HR, 0.33 [95% CI, 0.18 to 0.60]; P < .001), whereas the standard-risk group had favorable outcomes regardless of allogeneic HSCT. CONCLUSION Our findings challenge the significance of BCR::ABL1 monitoring in adult Ph+ ALL and demonstrate the prognostic role of IG/TR MRD. This study provides a framework for using MRD to guide treatment strategies in adults with Ph+ ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology Laboratory, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
- INSERM U944, CNRS UMR 7212 GenCellDis, Institut de Recherche Saint-Louis (IRSL), Paris, France.
- Division of Hematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- Swiss Group for Clinical Cancer Research (SAKK).
- Hematology Department, Centre Hospitalier de Versailles, Unité mixte de recherche 1184 Commissariat à l'Energie Atomique, University Paris-Saclay, Le Chesnay, France.
- EA 3518, Institut de Recherche Saint-Louis (IRSL), Université Paris Cité, Paris, France.
ORCID-Profile: Rathana Kim, Yves Chalandon, Marie Passet, Patrice Chevallier, Sylvain Chantepie, Sébastien Maury, Eolia Brissot, Emmanuelle Tavernier, Carlos Graux, Hervé Dombret, Nicolas Boissel, Emmanuelle Clappier
Zitieren
APA
Kim, R., Chalandon, Y., Rousselot, P., Cayuela, J. M., Huguet, F., Balsat, M., Passet, M., Chevallier, P., Hicheri, Y., Raffoux, E., Leguay, T., Chantepie, S., Maury, S., Hayette, S., Solly, F., Braun, T., De Prijck, B., Cacheux, V., Salanoubat, C., …, & Clappier, E. (2024). Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study. Journal of Clinical Oncology, 42(26), 3140-3150. https://doi.org/10.1200/jco.24.00108
Vancouver
Kim R, Chalandon Y, Rousselot P, Cayuela JM, Huguet F, Balsat M, et al. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study. Journal of Clinical Oncology. 2024;42(26):3140-3150. doi:10.1200/jco.24.00108
BibTeX
@article{Kim2024,
author = {Kim, Rathana and Chalandon, Yves and Rousselot, Philippe and Cayuela, Jean-Michel and Huguet, Françoise and Balsat, Marie and Passet, Marie and Chevallier, Patrice and Hicheri, Yosr and Raffoux, Emmanuel and Leguay, Thibaut and Chantepie, Sylvain and Maury, Sébastien and Hayette, Sandrine and Solly, Françoise and Braun, Thorsten and De Prijck, Bernard and Cacheux, Victoria and Salanoubat, Celia and Farnault, Laure and Guibaud, Isabelle and Lamarque, Mathilde and Gastaud, Lauris and Lemasle, Emilie and Brissot, Eolia and Tavernier, Emmanuelle and Bilger, Karine and Villate, Alban and Soulier, Jean and Graux, Carlos and Lhéritier, Véronique and Dombret, Hervé and Boissel, Nicolas and Clappier, Emmanuelle},
title = {Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {26},
pages = {3140--3150},
doi = {10.1200/jco.24.00108}
}
EUVIMED